Lantern Pharma (LTRN) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Lantern Pharma in September 2026.
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 200 billion oncology-focused data points and a library of 200+ ML algorithms. It is engaged in the development of its pipeline of drug candidates that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate program. Its portfolio includes a Phase II clinical program (LP-300) in NSCLC focused on never-smokers and non-smokers with the EGFR exon 21 L858R mutation; planned Phase I b/II trials (LP-184) in precision, biomarker-defined solid tumors, and an ongoing Phase II program in hematologic malignancies and adult soft tissue sarcomas (LP-284). It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.
